Piperidine derivatives as liver X receptor beta agonists, compositions, and their use

A compound having the structural Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• X is selected from CH and N;
• Y is selected from NH, N(CH3), S, S(O), S(O)2 and CH2;
• R1 is selected from H, methyl, and halogen;
• R2 is selected from H, halogen, cyano, cyclopropyl, —CH3, and —OCH3;
• R4 is selected from H, halogen, and methyl;
• -L- is selected from —C(O)— and —S(O)2—;
• R3 is —N(RN1)(RN2), wherein:
• RN1 is selected from H and —(C1-C6)alkyl;
• and
• RN2 is selected from H, —(C1-C6)alkyl, cyclopropyl, —O—(C1-C6)alkyl, —OH, halogen, —CN, and —(C1-C6)alkyl which is substituted with 1 or 2 groups independently selected from:
• —OH, halogen, —CN,
• optionally substituted phenyl, (wherein said optional substitutents on said phenyl are 1 to 3 groups independently selected from OH, CN, —(C1-C4)alkyl, and —(C1-C4)alkoxyl),
• optionally substituted heteroaryl, (wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from —(C1-C6)alkyl, —(C1-C4)alkoxyl, and cyclopropyl),
• optionally substituted cyclopropyl (wherein said optional substituents on said cyclopropyl are 1 to 3 groups independently selected from —(C1-C6)alkyl), and
• optionally substituted heterocycloalkyl (wherein said optional substitutents on said heterocycloalkyl are 1 to 3 groups independently selected from halogen, —OH, oxo, CN, and —(C1-C6)alkyl),
• or, alternatively, RN1 and RN2 are taken together with the nitrogen atom to which they are shown attached to form a 4-, 5-, or 6-membered fully saturated heterocyclic ring comprising (including the nitrogen atom) 1, 2, or 3 ring heteroatoms selected from N, N-oxide, O, S, and S-oxide,
• wherein said heterocyclic ring is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from halogen, —OH, oxo, CN, —(C1-C6)alkyl, amino-substituted —(C1-C6)alkyl (wherein said amino is 1, 2, or 3 groups independently selected from —NH2, —N(C1-C4alkyl)2, —NH(C1-C4alkyl)), —O—(C1-C6)alkyl, —(C1-C6)alkyl-OH, —(C1-C6)haloalkyl, —C(O)O—(C1-C6)alkyl, cyclopropyl, spirocyclopropyl, —CH2—NHC(O)O—(C1-C6)alkyl, —CH2—N(CH3)C(O)O—(C1-C6)alkyl, phenyl, benzyl, —NHC(O)-phenyl, heteroaryl, (C1-C4)alkylheteroaryl, and heterocycloalkyl;
• -L1- is a divalent moiety selected from:
• Q is a bond or a divalent moiety selected from —C(O)—, and —S(O)2—, and—
• R5 is —C(R5A)(R5B)(R5C), wherein:
• each of R5A, R5B and R5C is independently selected from:
• H, halogen, OH, NH2, NHCH3, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C1-C6)alkenyl, —(C1-C6)alkynyl, —(C3-C6)cycloalkyl, —(C3-C6)cycloalkyl substituted with —(C1-C6)alkyl, —(C1-C6)alkenyl, —(C1-C6)alkynyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from halogen, OH, —NH2, —(C1-C6)alkyl, —O—(C1-C6)alkyl, cyclopropyl, —O—(C1-C6)haloalkyl, —O-cyclopropyl, and —C(O)O—(C1-C6)alkyl,
• or R5 is
• wherein n is an integer from 1 to 4;
• wherein R5D is selected from H, —(C1-C6)alkyl, —(C1-C6)haloalkyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from OH, halogen, —(C1-C6)alkyl, and —O—(C1-C6)alkyl,
• or R5 is selected from phenyl and benzyl, wherein:
• said phenyl and said benzyl are unsubstituted or substituted with 1, 2, or 3 groups independently selected from halogen, CN, —(C1-C6)alkyl, and —(C1-C6)haloalkyl.